The Concordance Rates between LV Hypertrophy and RV Hypertrophy in Patients with Hypertrophic Cardiomyopathy as Diagnosed by Cardiovascular MRI with Fibrosis Imaging

Nessim N. Amin^*, Saundra B. Grant, June A. Yamrozik, Ronald B. Williams, Diane V. Thompson, Mark Doyle, Moneal Shah, Robert W. W. Biederman

Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.

DOI: 10.4236/wjcd.2015.57020                

Abstract

Introduction: CMR has become the leading modality to define the clinical impact of hypertrophic cardiomyopathy (HCM). Late gadolinium enhancement (LGE) accurately identifies regions of myocardial fibrosis. It is well known that myocardial fibrosis can occur in patients with HCM and is independently linked to a poorer prognosis than those without fibrosis by CMR. Hypothesis: We hypothesize that there is significant RV involvement in HCM when incorporates a CMR analysis for RV hypertrophy and fibrosis. Methods: A retrospective review of all patients referred for HCM was performed. SSFP/LGE techniques were used to diagnose patients with HCM, using gadolinium administration (0.15 mmol/kg). Post-injection (10 minutes) LGE images were obtained using manual T1-weighted, IR-preparations. Regions of myocardium with LGE signals were visually designated as fibrotic. LV/RV mass indices (LVMI/RVMI) and ejection fractions were calculated. Results: Via 72 patients referred for HCM, 47(65%) were CMR confirmed. The mean LVMI was 108 ± 44 g/m2 while the mean RVMI was 30 ± 21 g/m2. As well, 34/47 (72%) had evidence of LV fibrosis while 24/47 (51%) had evidence for RV fibrosis. Of the RVH positive patients, 26/34 (76%) patients were LV LGE positive and 18/34 (52%) were RV LGE positive. Conclusion: The high frequency of RVH and RV fibrosis in the setting of HCM is surprising in that this phenomenon is rarely described. However, there is no reason to expect the phenotypic expression should be limited to the LV. Interestingly, as for the LV, the presence or absence of RV fibrosis has little predictive power towards the systolic function.

Keywords

Cardiac MRI, Right Ventricle, Hypertrophic Cardiomyopathy, Fibrosis Imaging, Hypertrophy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Maron, B.J. (2002) Hypertrophic Cardiomyopathy: A Systematic Review. JAMA, 287, 1308-1320. http://dx.doi.org/10.1001/jama.287.10.1308
[2]	Maron, B.J., McKenna, W.J., Danielson, G.K., et al. (2003) American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Journal of the American College of Cardiology, 42, 1687-1713. http://dx.doi.org/10.1016/S0735-1097(03)00941-0
[3]	Elliott, P.M., Poloniecki, J., Dickie, S., et al. (2000) Sudden Death in Hypertrophic Cardiomyopathy: Identification of High Risk Patients. Journal of the American College of Cardiology, 36, 2212-2218. http://dx.doi.org/10.1016/S0735-1097(00)01003-2
[4]	Spirito, P., Bellone, P., Harris, K.M., Bernabo, P., Bruzzi, P. and Maron, B.J. (2000) Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy. The New England Journal of Medicine, 342, 1778-1785. http://dx.doi.org/10.1056/NEJM200006153422403
[5]	Wigle, E.D., Rakowski, H., Kimball, B.P. and Williams, W.G. (1995) Hypertrophic Cardiomyopathy: Clinical Spectrum and Treatment. Circulation, 92, 1680-1692. http://dx.doi.org/10.1161/01.CIR.92.7.1680
[6]	Seidman, J.G. and Seidman, C. (2001) The Genetic Basis for Cardiomyopathy: From Mutation Identification to Mechanistic Paradigms. Cell, 104, 557-567. http://dx.doi.org/10.1016/S0092-8674(01)00242-2
[7]	Richard, P., Charron, P., Carrier, L., et al. (2003) EUROGENE Heart Failure Project. Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy. Circulation, 107, 2227-2232. http://dx.doi.org/10.1161/01.CIR.0000066323.15244.54
[8]	Mozaffarian, D. and Caldwell, J.H. (2001) Right Ventricular Involvement in Hypertrophic Cardiomyopathy: A Case Report and Literature Review. Clinical Cardiology, 24, 2-8. http://dx.doi.org/10.1002/clc.4960240102
[9]	McKenna, W.J., Kleinebenne, A., Nihoyannopoulos, P. and Foale, R. (1988) Echocardiographic Measurements of Right Ventricular Wall Thickness in Hypertrophic Cardiomyopathy: Relation to Clinical and Prognostic Features. Journal of the American College of Cardiology, 11, 351-358. http://dx.doi.org/10.1016/0735-1097(88)90101-5
[10]	Severino, S., Caso, P., Cicala, S., et al. (2001) Involvement in Right Ventricle in Left Ventricular Hypertrophy: Analysis by Pulsed Doppler Tissue Imaging. European Journal of Echo-cardiography, 1, 281-288. http://dx.doi.org/10.1053/euje.2000.0043
[11]	Noureldin, R.A., Liu, S., Nacif, M.S., et al. (2012) The Diagnosis of Hypertrophic Cardiomyopathy by Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance, 14, 17. http://dx.doi.org/10.1186/1532-429X-14-17
[12]	Papavassiliu, T., Germans, T., Flüchter, S., et al. (2009) CMR Findings in Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation. JCMR, 11, 34.
[13]	Petkow-Dimitrow, P., Klimeczek, P., Vliegenthart, R., Pasowicz, M., Miszalski-Jamka, T., Oudkerk, M., Podolec, P., Dubiel, J.S. and Tracz, W. (2009) Late Gadolinium Enhancement in Cardiovascular Magnetic Resonance in Patients with Hypertrophic Cardiomyopathy Complicated by Life-Threatening Ventricular Tachyarrhythmia. Kardiologia Polska, 67, 964-969.
[14]	Maron, M.S. (2012) Clinical Utility of Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 14, 13.
[15]	Alla, V.M., Koneru, S., Hunter, C. and Mooss, A. (2012) LGE and the Risk of Sudden Death in HCM. JACC: Cardiovascular Imaging, 5, 761-762. http://dx.doi.org/10.1016/j.jcmg.2012.05.004
[16]	Green, J.J., Berger, J.S., Kramer, C.M. and Salerno, M. (2012) Prognostic Value of Late Gadolinium Enhancement in Clinical Outcomes for Hypertrophic Cardimyopathy. JACC: Cardiovascular Imaging, 5, 370-377. http://dx.doi.org/10.1016/j.jcmg.2011.11.021
[17]	Silva, N., Paladino, A., Doyle, M., Reddy, S.T., et al. (2012) A Systematic Review for Sudden Cardiac Death in Hypertrophic Cardiomyopathy Patients with Myocardial Fibrosis: A CMR LGE Study. Circulation, 124, Article ID: A15932.
[18]	Maron, M.S., Hauser, T.H., Dubrow, E., et al. (2007) Right Ventricular Involvement in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 100, 1293-1298.
[19]	Maron, B.J., Towbin, J.A., Thiene, G., et al. (2006) American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113, 1807-1816. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.174287
[20]	Chan, R.H., Maron, B.J., Olivotto, I., et al. (2015) Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 116, 436-441.
[21]	Zhang, S., Yang, Z.G., Sun, J.Y., et al. (2014) Assessing Right Ventricular Function in Patients with Hypertrophic Cardiomyopathy with Cardiac MRI: Correlation with the New York Heart Function Assessment (NYHA) Classification. PLoS ONE, 9, e104312.
[22]	Bravo, P.E., Luo, H.C., Pozios, I., et al. (2015) Late Gadolinium Enhancement Confined to the Right Ventricular Insertion Points in Hypertrophic Cardiomyopathy: An Intermediate Stage Phenotype? European Heart Journal—Cardiovascular Imaging (In Press). http://dx.doi.org/10.1093/ehjci/jev154